Women with multiple pregnancies, accompanied with pregnancy complications such as abortion, GDM, and hypertensive disorders, using medication known to interfere thyroid hormones, or had a history of thyroid diseases were excluded
OASIS trials: establishing effective doses Phase 2 OASIS 1 findings: Tested multiple dose levels: 0.3mg, 0.6mg, 1.2mg, 2.4mg, 4.5mg weekly Duration: 26 weeks Primary endpoint: Weight loss at each dose Dose-response results: 0.3mg weekly: ~4% body weight loss 0.6mg weekly: ~6% body weight loss 1.2mg weekly: ~8% body weight loss 2.4mg weekly: ~10% body weight loss 4.5mg weekly: ~12% body weight loss Key insight: Clear dose-response relationship
There is no significant difference in biochemical remission rates or the degree of improvement in liver function indicators between the two treatments
Individuals with CIRS have reduced levels of oxygen since their NRF2 is obstructed, resulting in reduced levels of both VEGF, HIF1, and HO-1
elegans through the deep sequencing ( Drosophila through the screening of cell proliferation-regulating miRNAs
